Worth reading
69In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
8462000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 39th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)
発行・処分する株式数8,462,000Shares
Shares delivered during the month: 8,462,000 shares (all new shares)
Intended allottee
EVO FUND (allottee of the stock acquisition rights)
発行済株式総数
Exercise ratio subject to exercise restrictions: 10.0% (actual ratio below 10.0%)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥22.0, ¥24.0 or ¥27.0. Details of the exercise price adjustment provision and the adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 600,000 rights; exercised during the month: 84,620 rights; unexercised at month-end: 261,500 rights
Most recent equity financing
Timing 1 June 2026 / Type Issuance of Series 39 Stock Acquisition Rights (with an exercise price adjustment clause) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 39th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 8,462,000 shares (all new shares) |
| Intended allottee | EVO FUND (allottee of the stock acquisition rights) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 10.0% (actual ratio below 10.0%) |
| Total number of issued shares | 110,026,408 shares (as of the end of the month preceding the reporting month, including 101 treasury shares) → Not disclosed |
| Exercise price | Exercise price during the month: ¥22.0, ¥24.0 or ¥27.0. Details of the exercise price adjustment provision and the adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 600,000 rights; exercised during the month: 84,620 rights; unexercised at month-end: 261,500 rights |
| Most recent equity financing | Timing 1 June 2026 / Type Issuance of Series 39 Stock Acquisition Rights (with an exercise price adjustment clause) / Amount Not disclosed |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the exercise status for September 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.